OJR520 for Chronic Kidney Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 112 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
This trial is looking for healthy adults and those with chronic kidney disease to help test a new drug called OJR520. Participants will receive the drug and be monitored for safety and how the body processes it.
You may be able to join if
- I am between 18 and 65 years old.
- I can provide written informed consent.
- I am in good health as checked by medical tests.
You may not be able to join if
- I am a woman who can become pregnant.
- I am a sexually active man and do not want to use contraception.
- I have significant heart problems or serious medical conditions.
- I have had a stroke or heart attack in the past.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Loading trial locations…
Novartis Pharmaceuticals
+41613241111
CONTACT